Yeda Research and Develpment & Co. Ltd

Memorial Sloan Kettering Cancer Center

Seethrough Ltd.

Other

The Weizmann Institute of Science

Coloright Ltd.

Avigdor Scherz

Yoram Salomon

Alexander Brandis

Hugo Scheer

Leszek Fiedor

Doron Eren

Israel Grossinger

Arie Marcovich

Roie Yerushalmi

Michel Mercier

Nadav Grossinger

Eli Benny

Oksana Shlyk-Kerner

Ilan Samish

David Kaftan

Jorge Dinamarca

Karin Neimann

Efrat Rubinstein

Ohad Mazor

Daniel Wagner

Jonathan Coleman

Kwanghee Kim

Michal Neeman

Avraham Cohen

Eliyahu Benny

Gerhard Hartwich

Philip A Watson

Nina Kammhuber

Lilach Agemy

Assaf Gilead

Shimon Gross

Liat Goldshaid

Dina Preise

Rachel Hamri

An anti-myeloid-derived suppressor cells agent ('anti-MDSCs agent') and a bacteriochlorophyll derivative (hereinafter 'Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).

Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.

(Bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders

A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).

Combination therapies for treatment of cancer

Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.

Conjugates of RGD peptides and (bacterio)chlorophyll photosensitizers

Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses

An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a Type II reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type II reaction center with an activity under a temperature range different than that of the type II reaction center endogenous to the photosynthetic organism. Also provided are methods of using the sequences for generating photosynthetic organisms or tailor-made thermotolerance.

Photosynthetic organisms and compositions and methods of generating same

RGD-chlorophyll and RGD-bacteriochlorophyll conjugates that home and accumulate in necrotic tumor domains much longer than in tumor non-necrotic domains are provided for use in minimally invasive tumor-targeted imaging, tumor-targeted photodynamic therapy, and/or on-line prognosis of necrotic tumors.

RGD-(bacterio)chlorophyll conjugates for photodynamic therapy and Imaging of Necrotic tumors

The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO&#x3c;&#x2212;&#x3e;, COS&#x3c;&#x2212;&#x3e;, SO3&#x3c;&#x2212;&#x3e;, PO3&#x3c;2&#x2212;&#x3e;, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17&#x3c;3&#x3e;, 13&#x3c;3&#x3e;, and 3&#x3c;2&#x3e; of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.

Water-soluble anionic bacteriochlorophyll derivatives and their uses

The invention provides cationic tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one positively charged group and/or at least one basic group that is converted to a positively charged group under physiological conditions, preferably Bchls having an onium group derived from a N-containing aliphatic or heterocyclic radical such as ammonium, guanidinium, imidazolium, pyridinium, and the like or a phosphonium, arsonium, oxonium, sulfonium, selenonium, telluronium, stibonium, or bismuthonium group, or a basic group that is converted to such onium groups under physiological conditions, said groups being bound to one or more of the positions 17&#x3c;3&#x3e;, 13&#x3c;3&#x3e; and 3&#x3c;2&#x3e; of the Bchl molecule by ester or amide bond. The Bchls are useful for photodynamic therapy and diagnosis.

Catatonic bacteriochlorophyll derivatives

Using a synthetic molecular spring device in a system for dynamically controlling a system property, such as momentum, topography, and electronic behavior. System features (a) the synthetic molecular spring device having (i) at least one synthetic molecular assembly each featuring at least one chemical unit including at least one: (1) atom; (2) complexing group complexed to at least one atom; (3) axial ligand reversibly physicochemically paired with at least one complexed atom; and (4) substantially elastic molecular linker; and, (ii) an activating mechanism directed to at least one atom-axial ligand pair; and, (b) a selected unit operatively coupled to synthetic molecular assembly, and exhibiting the system property. Activating mechanism sends an activating signal to atom-axial ligand pairs, for physicochemically modifying atom-axial ligand pairs, thereby activating at least one cycle of spring-type elastic reversible transitions between contracted and expanded linear conformational states of substantially elastic molecular linkers, causing dynamically controllable change in the system property.

Method using a synthetic molecular spring device in a system for dynamically controlling a system property and a corresponding system thereof

Synthetic molecular spring device featuring: (a) a synthetic molecular assembly, SMA, each scalable chemical module including: (i) at least one atom, M, (ii) at least one complexing group, CG, complexed to an atom, M, (iii) at least one axial ligand, AL, reversibly physicochemically paired with at least one atom, M, complexed to a complexing group, CG, (iv) at least one substantially elastic molecular linker, ML, having body and two ends with at least one chemically bonded to another component of SMA; (b) activating mechanism, AM, operatively directed to an atom-axial ligand pair, whereby following activating mechanism, AM, sending activating signal, AS/AS', to an atom-axial ligand pair for physicochemically modifying the atom-axial ligand pair, there is activating at least one cycle of spring-type elastic reversible transitions between contracted and expanded linear conformational states of molecular linker, ML. Optionally includes (v) chemical connectors, CC, and/or, (vi) binding sites, BS.

Synthetic molecular spring device

An online Blood Oxygenation Level-Dependent (BOLD)-magnetic resonance imaging (MRI) method for functional clinical guidance or monitoring a therapeutic modality involving treatment by a sensitizer which, upon excitation by the appropriate sensitizing radiation, initiates local oxygen consumption, comprising: (i) generating a BOLD-weighted MR-image of the target region of interest within the patient's body (time t); (ii) administering said sensitizer to the patient; (iii) irradiating the target region while the patient is subjected to continuous MR imaging; (iv) generating a sole or a plurality of T2* weighted sequential BOLD MR-images during and/or after irradiation (time t); (v) processing the data generated at time tand time t and generating a color-coded difference or ratio map on a pixel by pixel basis; and (vi) analyzing the processed data. The method is preferably applied to photodynamic therapy (PDT).

Sensitized online BOLD-MRI imaging method

Growing community of inventors

Rehovot, Israel

Avigdor Scherz